Biotechnology News and Research

RSS

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Charles River Laboratories International, Inc., a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech, a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion.

26 Apr 2010

Charles River Laboratories International reports 1.4% decline in first-quarter 2010 net sales

Charles River Laboratories International, Inc. today reported its results for the first quarter of 2010. For the quarter, net sales were $297.3 million, a decline of 1.4% from $301.5 million in the first quarter of 2009. The decrease was net of a foreign currency translation benefit of 3.4%. Higher sales for the Research Models and Services (RMS) segment were offset by lower sales for the Preclinical Services (PCS) segment.

26 Apr 2010

Physician panel to discuss issues related to Qutenza at Investor Day

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and CEO, and members of the NeurogesX management team, will host an Investor Day on Friday, April 30, 2010, from 8:15am-11:00am EDT in New York City

24 Apr 2010

CBSA hosts Career and Resource Fair for students and job seekers

The Colorado BioScience Association is hosting its second annual Career and Resource Fair Wednesday, April 28, from 1 to 4 p.m. at the Jefferson County Fairgrounds. The event will bring together students and job seekers looking to learn more about bioscience industry employment and training opportunities in the state.

24 Apr 2010

2010 Aggregate Spend and Disclosure Reporting Industry Survey of compliance program experts

Cegedim Dendrite today announced the results of the 2010 Aggregate Spend and Disclosure Reporting Industry Survey of compliance program experts from Life Sciences companies. Cegedim Dendrite is the leading provider of Customer Relationship Management, Regulatory Compliance, Data Optimization and Marketing solutions designed specifically for the Life Sciences industry.

24 Apr 2010

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

Advanced Cell Technology, Inc. announced today that it has completed key animal studies in connection with its Phase I multicenter study using embryonic stem cell derived Retinal Pigment Epithelium (RPE) cells to treat patients with Stargardt's Macular Dystrophy (SMD), for which it filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) in November. The studies demonstrated an excellent safety profile with no safety signals such as tumors or ectopic tissues.

24 Apr 2010

Trinean launches DropSense96 and DropPlate 16 G for genomic DNA quantification

Only 6 months after the release of its ground-breaking DropSense 96 spectrophotometer, Trinean, pioneer in high throughput analysis of droplets of samples in microfluidic structures, is now launching another device that will set the tone in scientific circles: the DropPlate 16 G. This upgrade of the current microfluid disposable, the DropPlate 16 U, allows researchers to quantify 96 DNA/RNA samples of only 2 microl in less than 5 minutes.

24 Apr 2010

WuXi PharmaTech announces filing of 2009 annual report on Form 20-F

WuXi PharmaTech (Cayman) Inc. today announced that it filed its annual report on Form 20-F for the year ended December 31, 2009 with the Securities and Exchange Commission.

24 Apr 2010

Presidio Pharmaceuticals, Numerate conclude collaboration to discover new compounds targeting HCV

Presidio Pharmaceuticals, Inc., and Numerate, Inc., today announced that they have concluded their two-year collaboration to discover new compounds that target hepatitis C virus (HCV).

24 Apr 2010

New Jersey District Court jury finds Nycomed's U.S. Patent No. 4,758,579 not invalid: Teva

Teva Pharmaceutical Industries Ltd. announced today that a jury returned a verdict in the U.S. District Court for the District of New Jersey finding that Nycomed's U.S. Patent No. 4,758,579 is not invalid. The Court has reserved decision on the issue of what, if any, effect to give to the jury's determinations in connection with the obviousness-type double patenting defenses, which Teva has argued is to be decided by the Court.

24 Apr 2010

Continuous flow mechanical circulatory support devices improve outcomes in patients awaiting heart transplants

New data show improved outcomes, better survival rates and lower costs with the use of continuous flow mechanical circulatory support devices in patients awaiting heart transplants. Research will be presented this week during symposia at the International Society for Heart and Lung Transplantation (ISHLT) 30th Annual Meeting and Scientific Session at the Hilton Chicago.

24 Apr 2010

SuperSonic Imagine reports results of largest worldwide multicenter clinical breast study in ultrasound imaging

SuperSonic Imagine, the innovative medical imaging company based in Aix-en-Provence, France has unveiled some of the results of the largest clinical breast study ever undertaken in ultrasound imaging. The worldwide multicenter study, involving top clinicians in the breast radiology community, is assessing the clinical benefits of ShearWave™ Elastography in the ultrasonic evaluation of breast lesions.

24 Apr 2010

Moffitt Cancer Center reports increasing interest in ERCC1 Analysis test for selecting chemotherapy for NSCLC

Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

24 Apr 2010

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.

24 Apr 2010

Golub Capital provides $12.0M of senior subordinated debt to support recapitalization of IDT

Golub Capital today announced that it has provided $12.0 million of senior subordinated debt to support the recapitalization and ongoing growth of Integrated DNA Technologies, Inc. This transaction marks the first investment made by GC 2009 Mezzanine Partners, L.P., which is Golub Capital's sixth fund dedicated to middle market mezzanine debt financings.

From Integrated DNA Technologies 24 Apr 2010

Facet Solutions announces data from ACADIA lumbar stenosis pilot study

Facet Solutions, Inc. today announced that it has finished compiling two year data from its lumbar stenosis pilot study in the US. At two years, patients in the ACADIA™ study experienced significant and sustained improvement in Oswestry Disability Index, VAS back pain and VAS leg pain. There were no re-operations in any of the patients, and all patients met the definition of success for ODI improvement.

23 Apr 2010

IDEXX Laboratories' first-quarter 2010 revenues increase 14% to $268.5M

IDEXX Laboratories, Inc., today reported that revenues for the first quarter of 2010 increased 14% to $268.5 million, from $236.5 million for the first quarter of 2009. Organic revenue growth, as defined below, was 9%. Earnings per diluted share for the quarter ended March 31, 2010 increased 28% to $0.55, compared to $0.43 for the same period in the prior year.

23 Apr 2010

Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas

Oncolytics Biotech Inc. announced today that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and Professor, Neurosurgery and Physiology, the University of Alabama at Birmingham.

23 Apr 2010

Plant-based vaccine factory to produce vaccines and therapeutics within weeks of outbreaks

The Fraunhofer Center for Molecular Biotechnology in Newark, Delaware, the Fraunhofer Center for Manufacturing Innovation in Boston, Massachusetts, the Boston University College of Engineering, and the biopharmaceutical company iBio, Inc. in Newark, Delaware, announced today that they have developed a fully automated, scalable "factory" that uses natural (non-genetically-modified) green plants to efficiently produce large quantities of vaccines and therapeutics within weeks.

23 Apr 2010

Genmab reaches milestone for Arzerra under terms of collaboration with GSK

Genmab A/S announced today it has reached a milestone for Arzerra(ofatumumab) under the terms of its collaboration with GlaxoSmithKline.

23 Apr 2010

Biotechnology News and Research

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Charles River Laboratories International reports 1.4% decline in first-quarter 2010 net sales

Physician panel to discuss issues related to Qutenza at Investor Day

CBSA hosts Career and Resource Fair for students and job seekers

2010 Aggregate Spend and Disclosure Reporting Industry Survey of compliance program experts

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

Trinean launches DropSense96 and DropPlate 16 G for genomic DNA quantification

WuXi PharmaTech announces filing of 2009 annual report on Form 20-F

Presidio Pharmaceuticals, Numerate conclude collaboration to discover new compounds targeting HCV

New Jersey District Court jury finds Nycomed's U.S. Patent No. 4,758,579 not invalid: Teva

Continuous flow mechanical circulatory support devices improve outcomes in patients awaiting heart transplants

SuperSonic Imagine reports results of largest worldwide multicenter clinical breast study in ultrasound imaging

Moffitt Cancer Center reports increasing interest in ERCC1 Analysis test for selecting chemotherapy for NSCLC

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

Golub Capital provides $12.0M of senior subordinated debt to support recapitalization of IDT

Facet Solutions announces data from ACADIA lumbar stenosis pilot study

IDEXX Laboratories' first-quarter 2010 revenues increase 14% to $268.5M

Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas

Plant-based vaccine factory to produce vaccines and therapeutics within weeks of outbreaks

Genmab reaches milestone for Arzerra under terms of collaboration with GSK

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News